| name | ppgl-biochemical-cutoff-application |
| description | Applies specific cutoff values to interpret biochemical test results for PPGL diagnosis. Uses >3x upper limit of normal for screening tests (random urinary fractionated metanephrines corrected for creatinine, blood fractionated catecholamines, plasma-free fractionated metanephrines) and >2x upper limit of normal for 24-hour urinary fractionated catecholamines confirmation; triggers include interpreting urinary metanephrine screening results, evaluating 24-hour catecholamine excretion for confirmation, and determining if biochemical test meets diagnostic threshold for PPGL. |
PPGL Biochemical Test Cutoff Value Application
STEP 1 — Gather Information
Collect random urinary fractionated metanephrines (creatinine corrected), blood fractionated catecholamines, and plasma-free fractionated metanephrines.
STEP 2 — Rule In / Rule Out
If any screening test exceeds >3× upper limit of normal (ULN), rule in PPGL suspicion and proceed to confirmation; otherwise rule out PPGL and consider alternative diagnoses.
STEP 3 — Classify or Stratify
If 24-hour urinary fractionated metanephrines >3× ULN OR 24-hour urinary fractionated catecholamines >2× ULN OR plasma-free fractionated metanephrines > ULN, classify as biochemical PPGL positive; else classify as negative.
STEP 4 — Decide
If positive, proceed to imaging for tumor localization; if negative, consider alternative diagnoses or repeat testing after addressing pre‑analytical factors.
Clinical Guardrails / Mimics / Pitfalls
Avoid false positives from stress, caffeine, tyramine‑rich foods, tricyclic antidepressants, or improper sample handling; ensure fasting, 20–30 min supine rest, and creatinine correction for random urine; note plasma‑free metanephrines reimbursed only once under Japanese insurance for differential diagnosis.
Concrete Clinical Example
A 45‑year‑old with episodic headaches and hypertension shows random urinary metanephrine (creatinine corrected) at 4.2× ULN (>3×). Confirmation testing reveals 24‑hour urinary fractionated metanephrines 3.5× ULN (>3×) and urinary catecholamines 2.5× ULN (>2×). Biochemical PPGL is confirmed; imaging is pursued for localization.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165
